Optipharm Co., Ltd.

As of June 30, 2026, Optipharm Co., Ltd. carries a market capitalization of 62.93B, placing it among publicly traded companies globally. Its enterprise value stands at 63.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Optipharm Co., Ltd. has 14.67M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.66, and the price-to-book ratio stands at 2.56.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 63.76B versus a market cap of 62.93B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Optipharm Co., Ltd. maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.39, indicating elevated leverage, while an interest coverage ratio of -0.18 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Optipharm Co., Ltd. posted a negative return on equity (ROE) of -7.35, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.47, reflecting losses generated across the asset base. The company generates approximately 300.47M in revenue per employee across its workforce of 78.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.16 indicates how many times Optipharm Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Optipharm Co., Ltd.'s stock has declined approximately 12.16% over the past 52 weeks. The 50-day moving average sits at 4,655.60, while the 200-day moving average is 4,904.13.

Over the twelve months ended June 30, 2026, Optipharm Co., Ltd. generated 23.59B in revenue and converted that into -1.86B in net income, yielding earnings per share of -127.33. EBITDA reached -89.92M, while operating income came in at -1.78B.

As of June 30, 2026, Optipharm Co., Ltd. holds 9.33B in cash and equivalents against 10.16B in total debt, resulting in a net debt position of 6.15B. Total book value stands at 24.55B, with working capital of 2.05B providing operational flexibility.

Optipharm Co., Ltd. produced 71.23M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -696.61M in capital expenditures, free cash flow totaled -625.38M - equivalent to -42.78 per share.

Over the twelve months ended June 30, 2026, Optipharm Co., Ltd. posted a gross margin of 24.69, reflecting its pricing power and cost economics. The operating margin of -7.53 and net profit margin of -7.89 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.00: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.92, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Optipharm Co., Ltd. shareholders.

As of June 30, 2026, Optipharm Co., Ltd. has an Altman Z-Score of 1.85, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.